Cite
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
MLA
Tokunaga, Takayuki, et al. “Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.” Cancers, vol. 15, no. 5, Mar. 2023, p. 1568. EBSCOhost, https://doi.org/10.3390/cancers15051568.
APA
Tokunaga, T., Tateyama, M., Kondo, Y., Miuma, S., Miyase, S., Tanaka, K., Narahara, S., Inada, H., Kurano, S., Yoshimaru, Y., Nagaoka, K., Watanabe, T., Setoyama, H., Fukubayashi, K., Tanaka, M., & Tanaka, Y. (2023). Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 15(5), 1568. https://doi.org/10.3390/cancers15051568
Chicago
Tokunaga, Takayuki, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, et al. 2023. “Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.” Cancers 15 (5): 1568. doi:10.3390/cancers15051568.